Refine by
Disease Early Articles & Analysis
41 news found
Tempus, a leader in artificial intelligence and precision medicine, today announced the clinical launch of its minimal residual disease (MRD) test portfolio, including Tempus’ xM test and the xM (NeXT Personal® Dx) test by Personalis. The portfolio features both a tumor-naïve assay and a tumor-informed assay that are designed to help detect residual ...
ByTempus
In the face of emerging infectious diseases, early detection and swift response are critical to preventing widespread outbreaks. ...
OCT fundus cameras like the Topcon Maestro2 allow us to see a greater detailed image of the eye to find pathology and manage diseases early.” By cross-cutting the retina in a manner similar to an MRI machine, OCT’s high-resolution imaging creates a 3D map of a patient’s eye, enabling doctors to diagnose eye diseases in a single ...
Osteoporosis is a disorder that causes the bone density to reduce with time, making bones so weak they get fractured even with a light fall. Regular testing has many benefits as it is tracked by HEDIS (Healthcare Effectiveness Data and Information) to ensure early detection among women to manage their condition properly. Read on to know ...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner Roche (SIX: RO, ROG; OTCQX: RHHBY) provided an update on the GRADUATE I and II studies evaluating gantenerumab in people with early Alzheimer’s disease (AD). The studies did not meet their primary endpoint of slowing clinical decline. ...
Optina Diagnostics’ comprehensive technology facilitates early and non-invasive diagnostic tests for chronic diseases including neurodegenerative conditions with its highly differentiated hyperspectral retinal imaging camera, the Optina-4CTM, significantly improving standard clinical practices. ...
With a 26.8% prevalence of diabetes for people over the age of 65, there are 14.3 million seniors alone who are at risk of developing visual loss or blindness. Diabetic eye diseases are treatable, and blindness can be prevented for most patients with early detection and treatment. ...
Proprietary microRNA signature (miRisk) may support immunotherapy treatment decisions as a blood-based complementary diagnostic Results published in Journal of Thoracic Oncology Clinical and Research Reports Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today announced a publication ...
Our mission remains to diagnose disease early and treat patients early with minimal hospital stays and no scars left ...
Collectively, Freeman, Datta and Henehan bring decades of experience building and growing financially successful biopharma and healthcare intelligence companies. In early April 2022, VIDA received market authorization in Japan for its VIDA Insights software, which is a complementary data-driven solution used by lung care teams at the point of care, aiding them to detect ...
We have submitted our third Commercialization Readiness Pilot (CRP) Program grant application to the National Institutes of Health (NIH). In it, we describe our plan to commercialize i-RxTherm, our device for early diabetic peripheral neuropathy detection and diagnosis. ...
“We are committed to providing the highest quality service to healthcare professionals, and the integration of our tests with Epic, which will include Guardant SHIELD™, our blood test to screen for early signs of colorectal cancer, will help to increase the scale and adoption of our offerings in both community practices and large health ...
Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today announced the publication of a study in the journal npj Precision Oncology that describes the discovery and validation of miRisk, a first-of-its-kind microRNA (miRNA) biomarker signature that offers the prospect of a blood-based ...
“We envision a world in which next generation medical robots help diagnose disease and treat patients early to ensure minimal hospital stays and quick recoveries,” said Zhang, Noah Medical’s founder and CEO. ...
An assay time of 50-70mins enables rapid diagnosis of the disease at the early and highly infectious stage of infection. Healthcare Access HiberGene Diagnostics Ltd worked with HIHI to facilitate the assessment of HiberGene’s PCR Adapt COVID-19 RT-qPCR test against two commercially available standard tests. ...
The KBCT is expected to optimize early disease detection, diagnosis, intervention, and treatment, and will improve survival rates for millions of patients worldwide. ...
Recently, the company announced the launch of biomarker and target discovery service for disease identification, early diagnosis and prevention, and monitoring during treatment. With the development of high-throughput sequencing technology, new biomarkers can not only be used as indicators for disease diagnosis and later judgment, but also as ...
The KBCT is expected to optimize early disease detection, diagnosis, intervention and treatment, and will improve survival rates for millions of patients worldwide. ...
This would provide the tools they need to effectively screen for disease and manage care early in the patient care ...
The KBCT is expected to optimize early disease detection, diagnosis, intervention and treatment, and will improve survival rates for millions of patients worldwide. ...